MedTrace Logo

Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease

NCT01526330 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2015-05-29

No results posted yet for this study

Summary

The objective of this study is to assess the safety and tolerability of YH14618 during 24 weeks of follow-up period after single administration in patients with degenerative disc disease.

Conditions

  • Degenerative Disc Disease

Interventions

DRUG

YH14618

A mg/disc

DRUG

YH14618

B mg/disc

DRUG

YH14618

C mg/disc

DRUG

Placebo

0mg/disc

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Young-joon Kwon, MD, PhD. · Kangbuk Samsung Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-01-31
Completion
2014-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01526330 on ClinicalTrials.gov